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Abstract
Aims: There is seasonal variation in the incidence of gestational diabetes (GDM) 
and delivery outcomes of affected patients. We assessed whether there was also evi-
dence of temporal variation in maternal treatment requirements and early neonatal 
outcomes.
Methods: We performed a retrospective analysis of women diagnosed with GDM 
(75 g oral glucose tolerance test, 0 h ≥ 5.1; 1 h ≥ 10.0; 2 h ≥ 8.5 mmol/L) in a UK 
tertiary obstetric centre (2015– 2019) with a singleton infant. Data regarding demo-
graphic characteristics, total insulin requirements and neonatal outcomes were ex-
tracted from contemporaneous electronic medical records. Linear/logistic regression 
models using month of the year as a predictor of outcomes were used to assess annual 
variation.
Results: In all, 791 women (50.6% receiving pharmacological treatment) and 790 
neonates were included. The likelihood of requiring insulin treatment was highest 
in November (p  <  0.05). The average total daily insulin dose was higher at peak 
(January) compared to average by 19 units/day (p < 0.05). There was no temporal 
variation in neonatal intensive care admission, or neonatal capillary blood glucose. 
However, rates of neonatal hypoglycaemia (defined as <2.6 mmol/L) were highest in 
December (40% above average; p < 0.05).
Conclusions: Women with GDM diagnosed in winter are more likely to require insu-
lin treatment and to require higher insulin doses. Neonates born to winter- diagnosed 
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1 |  INTRODUCTION
Evidence suggests that the likelihood of developing gesta-
tional diabetes (GDM) is influenced by external environmen-
tal factors, including variation by season. Seasonal differences 
in GDM risk have been demonstrated in diverse climates 
around the world from temperate to subtropical, includ-
ing North America,1 South America,2 Australia,3 Asia4 and 
Europe.5,6 Globally, there is a consistently higher incidence 
of GDM in hotter months. The reason for temporal variation 
in GDM incidence is not fully understood but could reflect 
either the impact of ambient temperature on blood glucose 
measurement7 or seasonal differences in diet and lifestyle.
Recent evidence from our centre suggests that pregnancy out-
comes also vary seasonally in pregnancies affected by GDM,5 
with higher birthweights and a corresponding increase in the 
risk of emergency Caesarean section during colder months. 
However, it is not known whether maternal treatment require-
ments or neonatal outcomes in GDM vary throughout the year.
Evidence suggests that insulin resistance at GDM diag-
nosis is highest in colder months.3 Higher insulin resistance 
at diagnosis is associated with increased requirement for 
insulin and higher mean maximum daily insulin dose,8 sug-
gesting that GDM treatment requirements might be greater in 
colder months. However, post- load glucose levels (assessed 
using oral glucose tolerance test; OGTT) tend to be higher 
in warmer months.2,3,6 As increased post- load glucose lev-
els are also associated with increased insulin requirements 
in GDM,9 it could also be the case that the need for insulin 
treatment may be reduced in colder months.
As proactive intervention to control maternal hypergly-
caemia leads to improved outcomes,10 an understanding of 
differing treatment requirements by season could be valuable 
in personalising care for women with GDM. We aimed to 
assess whether there is temporal variation in the treatment re-
quirements and neonatal outcomes of women diagnosed with 
GDM in the context of a relatively temperate climate in the 
United Kingdom.
2 |  METHODS
A cohort of 791 women diagnosed with GDM who deliv-
ered singleton infants at term (37– 42  weeks of gestation) 
from January 2015 to January 2019 at The Rosie hospital, 
Cambridge was identified as part of a service evaluation which 
had prospective institutional approval. The records of 790 neo-
nates were also available for analysis. Detailed hand- searching 
of the mothers' and babies' electronic medical records enabled 
collection of data regarding treatment and maternal and neo-
natal outcomes. The data were extracted retrospectively from 
routine documentation of patient encounters and were not col-
lected specifically for study purposes. Where a woman had two 
or more full- term pregnancies affected by Gestational diabetes 
(GDM) and otherwise eligible for inclusion within the study 
window, we only included the first pregnancy in the analysis. 
The primary outcome of this study was maternal treatment 
modality for GDM, specifically treatment with insulin. We 
included other details of the treatment regimen (total units of 
insulin), neonatal hypoglycaemia and neonatal lowest blood 
glucose as secondary outcomes.
Diagnosis of GDM was made based upon International 
Association of Diabetes in Pregnancy Study Groups (IADPSG) 
recommendations (75  g OGTT, 0  h  ≥  5.1; 1  h  ≥  10.0; 
mothers had a corresponding increased risk of neonatal hypoglycaemia. Maternal 
treatment requirements and neonatal outcomes of GDM vary significantly throughout 
the year, even in a relatively temperate climate.
K E Y W O R D S
gestational diabetes, pregnancy, temporality, seasonality, birthweight, obstetric outcomes, climate
What is already known?
• Rates of GDM and related pregnancy outcomes, 
including birthweight centile and emergency cae-
sarean section rates, show seasonal variation
• It is unclear if temporal variation also influences 
maternal treatment requirements or other neonatal 
complications
What this study has found?
• Women diagnosed in November were more likely 
to need insulin treatment. In winter, women re-
quired 19  units/day more insulin compared to 
summer- diagnosed women
• The incidence of neonatal hypoglycaemia also 
varied with season
What are the clinical implications of the study?
• Insulin treatment requirements in GDM and neo-
natal hypoglycaemia rates show significant an-
nual variation, even in a temperate climate.
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2 h ≥ 8.5 mmol/L).11 Women with risk factors for GDM were 
offered a 75 g OGTT at 24– 28 weeks as per NICE guidelines,12 
and additional OGTTs were offered to women on an ad hoc 
basis, for example based on results of random plasma glucose 
tests or growth scans. Women with previous GDM were offered 
capillary glucose self- monitoring or 75 g OGTT as soon as pos-
sible after booking (usually 11– 16 weeks of gestation).
After diagnosis of GDM, women were advised to take 
regular capillary glucose measurements and given detailed 
dietary and lifestyle advice. Women with persistent hypergly-
caemia despite dietary and lifestyle changes were offered es-
calating treatment, using metformin and/or insulin, to achieve 
target capillary glucose of fasting level <5.3 mmol/L and 1- 
hour postprandial level <7.8 mmol/L.
After delivery, all infants had pre- feed capillary glucose 
readings taken from 4 h after birth until there were three consec-
utive pre- feed readings ≥2.6 mmol/L. Readings <2.6 mmol/L 
were considered consistent with neonatal hypoglycaemia and 
treated with increased breastfeeding, expressed breast milk or 
formula until target blood glucose levels were met or treatment 
escalated, for example with IV dextrose.
Maternal demographic data collected included maternal 
age, ethnicity, BMI at booking and smoking status during 
pregnancy. Obstetric history included previous GDM, par-
ity (collapsed into 0, 1 or ≥2) and previous delivery mode 
(caesarean section or vaginal delivery). Gestation at diagnosis 
and results of OGTT and HbA1c at diagnosis were recorded. 
Treatment data consisted of treatment modality (diet, met-
formin, insulin or both) and maximal dosage required (for 
pragmatic reasons taken to be at 36 weeks). 14- day average 
blood glucose readings (mmol/L) and gestational weight gain 
(kg) were recorded for all women at the time of each appoint-
ment. Delivery variables were delivery mode (spontaneous or 
instrumental vaginal delivery, or caesarean section) and esti-
mated blood loss (ml).
Neonatal outcomes included sex, birthweight, neonatal 
capillary glucose readings, neonatal hypoglycaemia, jaun-
dice and admission to neonatal intensive care unit (NICU). 
Birthweight centiles were adjusted for gestational age and 
sex, using Intergrowth 21st standards.13
Group- wise comparisons were carried out using either 
Student's t- test or the Mann– Whitney test for numerical data, 
and Pearson's chi- squared test for categorical data. We ana-
lysed the likelihood of each outcome of interest dependent 
on the month of the year. We ran two separate models for 
maternal and neonatal outcomes. For maternal treatment out-
comes, the day of interest was at 28  weeks. This day was 
selected to best reflect the date that GDM would have been 
diagnosed and maternal treatment decisions would have 
been made for all patients in the cohort (accepting that for 
some women, treatment may be altered up to and beyond 
36  weeks). For neonatal outcomes, the day of interest was 
the day of delivery. This day was selected to best represent 
the day on which the neonatal outcome occurred, accepting 
that for some babies there may be a delay between delivery 
and outcome. Linear or logistic regression models were con-
structed for each outcome of interest with a dummy variable 
for month of the year. All models were adjusted for individual 
covariates, which were selected to optimise the Akaike infor-
mation criterion; booking BMI, ethnicity and parity.
As a secondary analysis, generalised additive modelling 
(GAM) was used to allow non- parametric model fitting 
with relaxed assumptions about the functional form of the 
relationship between day of the year, treated as a continu-
ous function, and outcomes of interest. The models were 
constructed by iteratively fitting weighted additive models 
through backfitting and were specified using the R package 
‘gam’ (https://cran.r- proje ct.org/web/packa ges/gam/gam.
pdf). The backfitting algorithm is a Gauss– Seidel method 
for fitting additive models by iteratively smoothing partial 
residuals. Our models incorporated a nonlinear term for the 
effect of day of year on the risk of each outcome, estimated 
using cubic splines, and were adjusted for booking BMI, eth-
nicity and parity. The risk of any given outcome for each 
day of the year is compared to the average risk calculated 
over the entire study period, and visually represented on the 
figure plots. Caution should be exercised regarding the inter-
pretation of the GAM model estimates for the first and last 
few days of the year, as the modelling estimates rely on a 
neighbourhood of data from either side of the point of inter-
est. This is absent for one side of data at the extremes of the 
x- axis, increasing the uncertainty around these estimates and 
increasing the potential for bias. As a sensitivity analysis, we 
also ran models with day 1 designated as the 1st July rather 
than the 1st January. This did not substantively alter the re-
sults of our analyses (Figure S1).
Statistical significance of the nonlinear effect of day of 
year was assessed using a likelihood- ratio test.
Findings were considered statistically significant at an 
alpha level of 0.05. All analyses were conducted using the 
R statistical software package version 3.5.1.14 A ‘complete 
cases’ approach was adopted to missing data. Analysis based 
on BMI recordings later in pregnancy suggested that booking 
BMI values were likely to be missing at completely random 
in the study population.
3 |  RESULTS
3.1 | Participant characteristics
In all, 400/791 (50.6%) of women required pharmacological 
treatment for their GDM at 36  weeks. 11.8% were treated 
with metformin alone, 24.7% with insulin alone and 14.2% 
with both insulin and metformin (Table  1). The average 
birthweight in the cohort was 3308 g (±425 g; Table 2).
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3.2 | Treatment of GDM
The average glucose readings in the first 2  weeks post- 
diagnosis did not vary temporally and there was no temporal 
difference in gestational weight gain. The likelihood of requir-
ing treatment with diet or metformin did not vary temporally. 
However, the likelihood of requiring treatment with insulin 
did vary, being significantly increased for women who were 
28  weeks of gestation in November (p  <  0.05; Figure  1a). 
The likelihood of requiring insulin treatment was >40% 
above baseline November– January and >10% below baseline 
March– August (p < 0.05 for overall trend; Figure 1b).
T A B L E  1  Maternal demographic data, obstetric history and 
management (n = 791).
















25– 29 162 20.5
30– 34 117 14.8
35– 39 77 9.7
≥40 49 6.2
Unknown 184 23.3
















Not applicable 356 45.0
GDM diagnosis Frequency Percentage
Timing of OGTT
<24 weeks 79 10.0
24– 28 weeks 333 42.1
>28 weeks 365 46.1
No OGTT 14 1.8
(Continues)






HbA1c at diagnosis (%) 5.4 ±0.6






Metformin only 93 11.8






Treatment– doses required Median IQR
Mean total daily metformin 
dose at 36 weeks (g; 
n = 205)
1.5 1.0– 2.0
Median insulin dose at 36 weeks (units/day; n = 307)
Short- acting 6.0 1.0– 19.0
Long- acting 8.0 4.0– 16.0
Delivery Frequency Percentage
Delivery mode
Spontaneous vaginal delivery 368 46.5
Instrumented vaginal delivery 104 13.1
Elective caesarean section 184 23.3
Emergency caesarean section 135 17.1




T A B L E  1  (Continued)
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The total insulin requirement among women treated 
with insulin (n  =  307) was significantly increased in 
women who were 28  weeks of gestation in January 
(p < 0.01; Figure 1c). The total insulin requirement in the 
cohort varied by 19  units/day from the highest require-
ment in January to the lowest in July (p < 0.05 for over-
all trend; Figure  1d). We also assessed the effects upon 
short- acting and long- acting insulin use. The number of 
units of short- acting insulin given per day was signifi-
cantly higher in women who were 28 weeks of gestation 
in January (p < 0.05; Figure 1e). When assessed by over-
all trend throughout the year, short- acting insulin require-
ment varied by 16 units from greatest (January) to lowest 
(July) but this variation was not statistically significant 
(p = 0.07, n = 171; Figure 1f). There was no significant 
temporal variation in the number of units of long- acting 
insulin given per day (n = 268; Figure 1g,h).
3.3 | Obstetric and neonatal outcomes
There was no annual variation in birthweight nor in the num-
ber of large for gestational age babies (birthweight greater 
than 90th centile). The risk of delivery by emergency caesar-
ean section did not vary temporally.
The risk of neonatal hypoglycaemia was significantly 
increased in babies delivered in December (p  <  0.05; 
Figure 2a). When analysed as a continuous variable, the risk 
of hypoglycaemia varied by day of delivery from a high of 
40% above baseline in December to a low of 30% below base-
line in July (p < 0.05, Figure 2b). There was no annual varia-
tion in the number of babies admitted to NICU for any cause. 
When analysed either by month or as a continuous variable, 
neonatal capillary glucose did not show temporal variation 
(±0.15 mmol/L; Figure 2c,d).
4 |  DISCUSSION
We show that women diagnosed with GDM in winter months 
are more likely to require treatment with insulin and to need 
19  units/day more insulin, compared to women diagnosed 
in summer months. Women who delivered their baby in the 
summer months had the lowest GDM treatment requirements 
and a correspondingly lower risk of having a neonate with 
hypoglycaemia.
4.1 | Maternal and neonatal outcomes
The lack of temporal variation of maternal and neonatal out-
comes we found (with the exception of neonatal hypogly-
caemia) is reassuring as it suggests that escalating treatments 
at high- risk times may help to achieve the same outcomes 
throughout the year. Treatment for GDM is adjusted 
throughout pregnancy to achieve optimal glycaemic control. 
Addition of insulin occurs only when lifestyle modifications 
are not sufficient to keep blood glucose within the target 
range, which could result from greater insulin resistance or 
reduced engagement with non- pharmacological treatments 
such as diet and exercise. Increased risk of treatment with 
insulin may also be due to the effect of temperature on OGTT 
results causing differences in average severity of GDM diag-
nosed in winter compared to summer. A previous study at our 
centre reported significant seasonal variation in birthweight 
and rates of emergency caesarean section in GDM pregnan-
cies.5 The period of data collection was earlier (2004– 2008) 
than ours (2015– 2019), and the diagnostic criteria used 
were WHO 1999 and modified WHO 199915,16 rather than 
IADPSG criteria used in our study. It is possible that the tem-
poral variations in pharmacological management observed in 
the current cohort have eliminated the previous variations in 
clinical outcomes, but it is not possible to test this directly, 
due to lack of detailed information about treatment dosages 
in 2004– 2008.
Temporal variation in maternal hyperglycaemia and hence 
treatment requirement could impact risk of neonatal hypogly-
caemia. There are conflicting reports about whether maternal 
treatment affects the risk of neonatal hypoglycaemia with 
some studies finding increased risk if mothers required med-
ical treatment17 while others find no significant difference 
in risk between neonates of diet- treated and insulin- treated 
T A B L E  2  Neonatal outcome data (n = 790).














Not recorded 3 0.4
Mean ±SD
Birthweight (g) 3308 ±425
Lowest blood glucose 
(mmol/L)
2.6 ±0.6
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mothers.18 Although we found significant temporal variation 
in the risk of neonatal hypoglycaemia when treated as a cat-
egorical variable, it is important to note the annual range of 
mean lowest capillary glucose reading was <0.15  mmol/L 
and there was no significant temporal variation. Since the 
risk of adverse neurodevelopmental outcomes of hypoglycae-
mia depends upon severity of hypoglycaemia,19 it is doubtful 
whether such a small absolute difference would translate to 
a meaningful temporal difference in the most severe conse-
quences of neonatal hypoglycaemia, especially given that 
there was no temporal difference in rate of admission to 
NICU.
4.2 | Insulin resistance
Seasonal variation in glycaemic control has been dem-
onstrated in school- aged children with type 1 diabetes 20 
and adults with type 2 diabetes.21 In these studies, HbA1c 
was found to fluctuate seasonally with highest values re-
corded in winter. Insulin resistance, as calculated using the 
HOMA- IR equation, has been shown to be greater in win-
ter compared to summer in pregnant women both with and 
without GDM.3,22 The cause of the variation in insulin re-
sistance is not clear, although vitamin D has been proposed 
as a potential explanation. Low vitamin D levels show 
F I G U R E  1  The impact of temporal variation upon requirement for insulin treatment (a, by month; b, using generalised additive modelling 
[GAM], p[overall trend] <0.05), total number of units of insulin required (c, by month; d, GAM, p[overall trend] <0.05), number of units of 
short- acting insulin required (e, by month; f, GAM, p[overall trend] =0.07), number of units of long- acting insulin required (g, by month; h, GAM, 
p[overall trend] >0.1), All analyses were adjusted for booking BMI, ethnicity and parity. Horizontal lines represent the average taken across the 
entire year. Tick marks on the x- axis of GAM figures represent the number of individual data points included on each day of the year
F I G U R E  2  Temporal variation in risk of neonatal hypoglycaemia (a, by month; b, GAM, p[overall trend] <0.05), and lowest measured 
neonatal blood glucose concentration (c, by month; d, GAM, p[overall trend] >0.1). All analyses were adjusted for booking BMI, ethnicity and 
parity. Horizontal lines represent the average taken across the entire year. Tick marks on the x- axis of GAM figures represent the number of 
individual data points included on each day of the year
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seasonal variation and are associated with development of 
type 2 diabetes.23 Vitamin D deficiency has been shown to 
significantly increase the risk of developing GDM24 and 
a meta- analysis of trials of vitamin D supplementation in 
women with GDM showed that supplementation improved 
glycaemic control, decreasing both fasting plasma glucose 
and HbA1c.
25 However, a recent study analysing the im-
pact of both season and vitamin D on glucose homeostasis 
showed that they independently impact glucose homeo-
stasis suggesting that although vitamin D does influence 
seasonal variation in insulin resistance, it is not the sole 
contributor.22 Further research would be required to iden-
tify other contributing factors.
4.3 | Diet and exercise
Before pharmacological management, all women are ad-
vised to adopt a low glycaemic index diet and engage in 
physical activity but the ability to engage in these treat-
ments may vary seasonally. Nutrient intake varies in preg-
nancy according to season,26 and differences in dietary 
intake throughout the year including around holidays such 
as Christmas and Easter have been shown to contribute to 
seasonal variation in glycaemic control in type 2 diabet-
ics.27 Physical activity levels vary throughout the year with 
peak activity in summer28 and a qualitative study assess-
ing influences on physical activity in pregnancy identified 
unfavourable weather as a barrier.29 Support for indoor ex-
ercise could reduce the impact of the weather and a trial 
home- based indoor exercise has shown it to be beneficial 
in terms of improved glycaemic control in women with 
GDM.30
Our study has several important strengths including a 
large cohort managed at a single centre according to stan-
dardised protocols. The dataset was generated from hand- 
searching of a detailed electronic records system from 
documentation recorded at the time of clinical encounters. 
We use non- parametric dynamic additive models as a flexible 
way to determine the risks of outcomes relative to baseline 
risk at any time- point in the year while avoiding making any 
a priori assumptions about the relationship of risk to time or 
introducing arbitrary time divisions within the annual cycle.
There are limitations of this study. Some data were in-
complete, most notably maternal BMI was not recorded for 
23.3% of the participants. We excluded women who deliv-
ered preterm infants from this analysis (typically 9.9% of 
our population) as the risk of neonatal hypoglycaemia is 
much higher after preterm delivery. However, it is possible 
that this may have excluded women with most severe hy-
perglycaemia or coexisting related conditions such as pre- 
eclampsia leading to an underestimation of the risk for this 
population. Although the size of the cohort was large overall, 
subset analyses included a more limited number of women. 
The variables collected do not enable calculation of maternal 
insulin resistance. Further research is needed to determine 
whether these findings are replicated in other settings and 
whether adjustments such as vitamin D supplementation or 
supporting indoor exercise could improve glycaemic con-
trol and reduce pharmacological treatment requirements in 
women diagnosed with GDM in winter.
The temporal variation in treatment requirements and 
neonatal outcomes in GDM observed here is likely multifac-
torial. It is possible that the observed variance is primarily 
attributable to maternal behavioural differences throughout 
the year, particularly in diet/exercise patterns. However, it is 
also possible that GDM is less comprehensively monitored 
and treated in summer months, potentially due to service or 
lifestyle- related factors. This possibility appears less likely as 
previous studies indicate no increase in average birthweight 
during times of year when insulin treatment is reduced.5 
Future studies that include results of continuous glucose 
monitoring in GDM may help to further assess detailed cor-
relations between glycaemic control and insulin prescription.
In summary, this study demonstrates that the requirement 
for insulin treatment in GDM varies significantly throughout 
the year, even in a relatively temperate climate. We also iden-
tified temporal variation in risk of neonatal hypoglycaemia, 
particularly involving infants of mothers with correspond-
ingly high treatment requirements. Improved understanding 
of temporal effects allows better access to pharmacologi-
cal treatment and optimal surveillance to prevent neonatal 
complications.
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